AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00565396
Drug: Fosinopril and Losartan
RxNorm normalized name: fosinopril and diuretics
DrugBank: Fosinopril (DB00492)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
Trial: NCT01127633
Drug: Solanezumab
RxNorm normalized name: Solanezumab
DrugBank: Solanezumab (DB11756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
Trial: NCT01248442
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
Trial: NCT00374881
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine
Trial: NCT00374881
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine low dose
Trial: NCT00688467
Drug: Navarixin
RxNorm normalized name: Navarixin
DrugBank: Navarixin (DB11711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
Trial: NCT03497273
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib administered orally once daily at the protocol-defined dose.
Trial: NCT03765216
Drug: 2L Polyethylene Glycol (PEG)
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
Trial: NCT03765216
Drug: 4L Polyethylene Glycol (PEG)
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
Trial: NCT00690794
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
Trial: NCT00690794
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
Trial: NCT00358319
Drug: Karenitecin
RxNorm normalized name: Karenitecin
DrugBank: Cositecan (DB05806)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00358319
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01149330
Drug: Adapalene-BPO Gel
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply 1 gram of the investigational drug every night on whole face.
Trial: NCT00728156
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
Trial: NCT02588417
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
Trial: NCT02588417
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levobupivacaine 2.5 mg
Trial: NCT00005844
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02475551
Drug: IdeS
RxNorm normalized name: IdeS
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00355355
Drug: Talaporfin sodium
RxNorm normalized name: Talaporfin
DrugBank: Talaporfin (DB11812)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
Trial: NCT02101047
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00194467
Drug: valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 900 mg once a day for 8 weeks
Trial: NCT02056444
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02440204
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
Trial: NCT03220646
Drug: abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
Trial: NCT03220646
Drug: abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
Trial: NCT04594629
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
Trial: NCT04594629
Drug: PGI2
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
Trial: NCT03723798
Drug: SA001 Low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 tablets b.i.d for 12 weeks
Trial: NCT03723798
Drug: SA001 High dose
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets b.i.d for 12 weeks
Trial: NCT02366676
Drug: hyaluronic acid and chondroitin sulphate
RxNorm normalized name: chondroitin sulfates / hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)
Trial: NCT00506402
Drug: MKC-1
RxNorm normalized name: MKC-1
DrugBank: MKC-1 (DB05608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 30 mg and 100 mg, BID, continuous dosing
Trial: NCT00300950
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03318354
Drug: Torrent's Olmesartan Medoxomil Tablets 40 mg
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04039412
Drug: Levofloxacin quadruple regimen
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-Clarithromycin non-Bismuth quadruple therapy
Trial: NCT03352323
Drug: Oxymetazoline
RxNorm normalized name: Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RLD
Trial: NCT00130221
Drug: 2% chlorhexidine gluconate impregnated cloth
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03350451
Drug: Lumasiran
RxNorm normalized name: lumasiran
DrugBank: Lumasiran (DB15935)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multiple doses of lumasiran by SC injection
Trial: NCT03439670
Drug: Vamorolone
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 2.0 mg/kg/day for the duration of the study.
Trial: NCT03439670
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 0.75 mg/kg/day for 24 weeks.
Trial: NCT03439670
Drug: Vamorolone
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 6.0 mg/kg/day for the duration of the study.
Trial: NCT03439670
Drug: Vamorolone
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 2.0 mg/kg/day for 20 weeks.
Trial: NCT03439670
Drug: Vamorolone
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 6.0 mg/kg/day for 20 weeks.
Trial: NCT01420445
Drug: YHD001 dose level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times daily / 7 days
Trial: NCT01420445
Drug: YHD001 dose level 2
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times daily / 7 days
Trial: NCT01420445
Drug: Pelargonium sidoides extract
RxNorm normalized name: Pelargonium sidoides root extract
DrugBank: Pelargonium sidoides root (DB16583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-9mL three times daily / 7 days
Trial: NCT02273895
Drug: Scopolamine
RxNorm normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3 mg/mL, intravenously, once
Trial: NCT03297385
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
Trial: NCT03386942
Drug: Farletuzumab Ecteribulin
RxNorm normalized name: Farletuzumab ecteribulin
DrugBank: Farletuzumab ecteribulin (DB18857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
Trial: NCT03169582
Drug: Avanafil
RxNorm normalized name: Avanafil
DrugBank: Avanafil (DB06237)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug administration (Avanafil)
Trial: NCT03169582
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug administration (Sildenafil)
Trial: NCT00368654
Drug: Raptiva
RxNorm normalized name: Raptiva
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
Trial: NCT01285245
Drug: kineret
RxNorm normalized name: Kineret
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once daily 100 mg of kineret subcutaneously for 8 days
Trial: NCT03891420
Drug: Galidesivir
RxNorm normalized name: Galidesivir
DrugBank: Galidesivir (DB11676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galidesivir IV infusion
Trial: NCT01946373
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00944450
Drug: Sitagliptin phosphate anhydrous formulation
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
Trial: NCT00944450
Drug: Comparator: sitagliptin phosphate monohydrate form
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
Trial: NCT00233896
Drug: Oral beclomethasone dipropionate (drug)
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00930566
Drug: methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient.
Trial: NCT01680718
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
Trial: NCT01680718
Drug: Intranasal vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
Trial: NCT01951157
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder for solution for infusion
Trial: NCT01951157
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Powder for solution for infusion
Trial: NCT01951157
Drug: Lurbinectedin (PM01183)
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder for concentrate for solution for infusion
Trial: NCT02368795
Drug: Isosorbide Dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual Isosorbide dinitrate 5 mg before ERCP
Trial: NCT01239706
Drug: NTx 265
RxNorm normalized name: NTx-265
DrugBank: NTx-265 (DB05649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
Trial: NCT00001758
Drug: Abacavir
RxNorm normalized name: Abacavir
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00001758
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00001758
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01423487
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5g bid 26 weeks
Trial: NCT00100126
Drug: Amoxicillin Pulsatile Release Multiparticluate Sprinkle
RxNorm normalized name: amoxicillin Extended Release Oral Tablet
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01831154
Drug: Tight Glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
Trial: NCT01831154
Drug: Conventional Glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
Trial: NCT00642239
Drug: Sodium Glycididazole
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
Trial: NCT00768300
Drug: Ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
Trial: NCT02439905
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Trial: NCT03249311
Drug: Levomilnacipran
RxNorm normalized name: Levomilnacipran
DrugBank: Levomilnacipran (DB08918)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Trial: NCT03249311
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Trial: NCT01100333
Drug: Recombinant human follicle stimulating hormone (r-hFSH)
RxNorm normalized name: Recombinant human follicle stimulating hormone beta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Recombinant hFSH prescribed according to prescriber's judgement
Trial: NCT00560092
Drug: intrathecal magnesium sulfate
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal magnesium sulfate
Trial: NCT01023217
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
Trial: NCT01023217
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir 1 mg/day orally
Trial: NCT01023217
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (Zeffix) 100 mg/day orally
Trial: NCT01673646
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
Trial: NCT03230318
Drug: derazantinib
RxNorm normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib was administered orally at 300 mg once daily
Trial: NCT01324960
Drug: Ceplene®, IL-2, Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
Trial: NCT01324960
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
Trial: NCT04389177
Drug: Pembrolizumab Injection [Keytruda]
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery.
Trial: NCT02439307
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 mg of rifaximin for 2 weeks.
Trial: NCT04098302
Drug: Dutasteride Capsules
RxNorm normalized name: Dutasteride Capsules
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/day oral dutasteride (2 x 0.5 mg capsules)